Aggressive prostate cancer halted with new treatment
The RADAR (Randomised Androgen Deprivation and Radiotherapy) trial enrolled 1071 men with newly-diagnosed aggressive but localised prostate cancer between 2003 and 2007 from 23 centres across Australia and New Zealand.
All men received six months of testosterone suppression therapy, using leuprorelin, followed by radiotherapy.
They were then randomly allocated to one of four groups – no further treatment, an extra 12 months of testosterone suppression, 12 months of zoledronic acid, or 12 months of testosterone suppression and zoledronic acid.
At five-year follow up, for men with the most aggressive cancers – Gleason scores of 8—10 – the combination of 18 months testosterone suppression therapy and zoledronic acid plus radiotherapy emerged as the most effective treatment.
Men with a Gleason score of seven or less benefited most from 18 months of testosterone suppression plus radiotherapy without